Guardant Health’s Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening Jul. 29, 2024 6:30 AM ...

Guardant Health’s FDA-approved Shield™ Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer Aug. 01, 2024 8:30 AM ET Guardant Health, Inc. (GH) ...

The first blood test for colorectal cancer was approved Monday by the Food and Drug Administration. Guardant Health's Shield test is for people 45 and older who are at average risk for the disease.

Guardant Health, Inc., a leading precision oncology company, today announced the Centers for Medicare& Medicaid Services has approved Advanced Diagnostic Laboratory Test status for the Shield ...

Guardant Health (GH) announced that the National Comprehensive Cancer Network, NCCN, has included the Shield blood test in its updated colorectal cancer, CRC, screening guidelines. The Shield test ...

PALO ALTO, Calif., March 25, 2025--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer (CRC) screening is now ...

On Monday, the FDA approved Guardant Health Inc.’s (NASDAQ:GH) Shield blood test for colorectal cancer (CRC) screening in adults age 45 and older who are at average risk for the disease. The ...

Shield, made by Guardant Health, is the first approved blood test that is considered a primary screening option for the disease. The FDA has approved a new blood test for colorectal cancer.

According to a news release from Guardant, however, Shield "is the first blood test to be approved by the FDA as a primary screening option for colorectal cancer, meaning healthcare providers can ...

Guardant Health, Inc., a leading precision oncology company, today announced the U.S. Food and Drug Administration has approved the company’ s Shield™ blood test for colorectal cancer ...

On Monday, the FDA approved Guardant Health Inc.’s GH Shield blood test for colorectal cancer (CRC) screening in adults age 45 and older who are at average risk for the disease.

PALO ALTO, Calif., July 29, 2024--The FDA has approved the Shield test from Guardant Health, the first blood test approved as a primary screening option for colorectal cancer.